Pennant Group’s Jason Paul Steik sells 218 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Pennant Group, Inc. (PNTG) Chief Clinical Officer Jason Paul Steik sold 218 shares of common stock on November 17, 2026, at $37.147 per share. The sale was made under a Rule 10b5-1 trading plan. Steik directly held 14,888 shares after the transaction.
Insider Trade Summary 10b5-1
Net Seller: 218 shares
Net Sell
1 txn
Insider
Steik Jason Paul
Role
Chief Clinical Officer
Sold
218 shs ($8K)
Share of Position Sold
1.4%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 218 | $37.147 | $8K |
Holdings After Transaction:
Common Stock — 14,888 shares (Direct)
Holdings Before and After:
Common Stock, 15,106 to 14,888 shares (Direct)
Key Figures
Shares sold: 218 shares
Sale price: $37.147 per share
Direct shares held after sale: 14,888 shares
3 metrics
Shares sold
218 shares
Common stock sale on November 17, 2026
Sale price
$37.147 per share
Common stock sale on November 17, 2026
Direct shares held after sale
14,888 shares
Jason Paul Steik's reported position following the transaction
Key Terms
Rule 10b5-1 trading plan
1 terms
Rule 10b5-1 trading plan regulatory
"sale was made under a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.